Symposium:
114. CMV: Pathogenicity Not Limited to Congenital and Transplant Infections
Friday, October 6, 2017: 8:30 AM-10:00 AM
Room: 17AB

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe how novel drugs and vaccines in development might be evaluated for their ability to control the excess mortality associated with CMV
  • identify future treatment goals for CMV infection in non-immunocompromised patients admitted to intensive care
  • describe strategies to identify the contribution of CMV to immunosenescence

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Infectious diseases physicians, Investigators, Researchers, Scientists, Vaccinologists

Tracks: Adult ID, Pediatric ID


Moderators:  Paul Griffiths, MD, DSc, University College London and Michael Boeckh, MD, PhD, FIDSA, Fred Hutchinson Cancer Research Center

Presentations:
8:30 AM
923
CMV in ICU patients
Ajit Limaye, MD, FIDSA

8:55 AM
924
CMV and Immunosenescence
Graham Pawelec, PhD

9:20 AM
925
9:45 AM
Q&A

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-266-L01-P

Disclosures:

P. Griffiths, Shire: member of end-points committee for trial of maribavir February 2017 onwards , honorarium paid to my employer not to me
Chimerix: Scientific Advisor , honorarium paid to my employer not to me

M. Boeckh, Merck: Investigator , Research Contractor and Scientific Advisor , Consulting fee and Research support
Astellas: Consultant , Investigator and Research Contractor , Consulting fee , Research grant and Research support
Chimerix: Consultant , Investigator and Research Contractor , Consulting fee , Research grant and Research support
Shire: Consultant and Investigator , Consulting fee and Research support
Artemis Therapeutics: Consultant , Consulting fee
Vir Biotechnologies: Consultant and Research Contractor , Consulting fee and Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.